A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies
Biotech startup Affini-T Therapetuics aims to use engineered T-cell receptors, or TCRs, to target the source of cancerous cells.
Read The StoryHealth
The latest developments affecting patients and practitioners. Sign up for our Morning Rounds newsletter to get the latest health and medicine news in your inbox.
A cascade of Omicron-driven shortages puts U.S. hospitals in a bind
Researchers shatter the speed record for diagnosing rare genetic diseases with DNA sequencing
‘I’m going to prove you wrong’: How a D.C. power couple used an ALS diagnosis to create a political juggernaut
